TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18420558
Drug: Randomized responding
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized responding technique (RRT) treatment group
Study: 9316691
Drug: Nimodipine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (120 mg/day)
Study: 20022777
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa or agalsidase beta in Cohort 1B
Study: 20022777
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) prior to October 2006 in Cohort 1A
Study: 18710324
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PPV) followed by protein‐conjugate pneumococcal vaccine (PCV)
Study: 18710324
Drug: Protein‐conjugate pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein‐conjugate pneumococcal vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV)
Study: 18710324
Drug: Protein‐conjugate pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein‐conjugate pneumococcal vaccine (PCV)
Study: 18710324
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PPV) as a booster after PCV
Study: 15695301
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (thalassotherapy, supervised exercise, and group education)
Study: 15695301
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (treatment as usual)
Study: 12112158
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication alone (Control)
Study: 2210464
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg daily for 12 weeks
Study: 2210464
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg daily for 12 weeks plus cefixime 100 mg daily for the last two weeks
Study: 31296884
Drug: Nitisinone 1
Normalized name: nitisinone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitisinone 1 mg daily
Study: 31296884
Drug: Nitisinone 2
Normalized name: nitisinone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitisinone 2 mg daily
Study: 31296884
Drug: Nitisinone 4
Normalized name: nitisinone 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitisinone 4 mg daily
Study: 31296884
Drug: Nitisinone 8
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nitisinone 8 mg daily
Study: 24112746
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol solution (initial dose 20μg/hour, increased by 20μg/hour every 6 hours up to 80μg/hour for a maximum of 48 doses)
Study: 24112746
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol tablets (25μg every 6 hours for a maximum of 8 doses)
Study: 21900191
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taliglucerase alfa (30 U/kg body weight/infusion)
Study: 21900191
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taliglucerase alfa (60 U/kg body weight/infusion)
Study: 19638025
Drug: Dual-task conditions
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task conditions (oral counting task)
Study: 17717929
Drug: Modified Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Xiaoyao Pill combining amitriptyline (MXP-At)
Study: 17717929
Drug: Fluoxetine (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (control group)
Study: 11587992
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (3 months)
Study: 9519224
Drug: Budesonide 4
Normalized name: budesonide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 4 mg nebulized suspension
Study: 9519224
Drug: Budesonide 1
Normalized name: BUDESONIDE 1MG/2ML SUSP,INH,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1 mg nebulized suspension
Study: 9519224
Drug: Budesonide 0.8
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.8 mg pMDI with spacer
Study: 2511532
Drug: Depot gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot gonadotropin-releasing hormone analogue (leuprolide) given monthly for 24 weeks
Study: 887103
Drug: Oral choline
Normalized name: choline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral choline administration for two weeks
Study: 30093401
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (2.5-10 mg/m2) administered in 1-4 cycles as a single agent (47%), combined with cytarabine (47%), or others (6%)
Study: 19737502
Drug: Paper-and-pencil Daily
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil Daily Social Diary (DSD)
Study: 17714104
Drug: 15 milliTESLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 milliTESLA (mT) treatment using a prototype electromagnetic field device
Study: 15113951
Drug: Medicinal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal iron supplements
Study: 9439541
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) infusion (25 ng/kg/min)
Study: 7886779
Drug: Aminosidine, 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminosidine, 14 mg/kg/d (max. 1 g daily) for 20 days
Study: 7886779
Drug: Sodium stibogluconate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate, 20 mg/kg/d for 20 days
Study: 26163093
Drug: Chemotherapy (CHT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHT) followed by short-course palliative RT: 2-3 platinum-based CHT cycles followed by 10Gy in a single fraction or 16Gy in 2 fractions (arm B)
Study: 15126606
Drug: Pre-diagnostic plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-diagnostic plasma selenium levels (5th versus 1st quintile) among case subjects with elevated baseline PSA levels (PSA >4 ng/mL)
Study: 7572650
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg 4 times daily
Study: 1690482
Drug: Prazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial)
Study: 376211
Drug: Trazodone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50 mg) 3 times a day
Study: 376211
Drug: Imipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25 mg) 3 times a day
Study: 7910886
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg followed by 250 mg daily for 7 days
Study: 26674497
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (oxycodone and pregabalin) plus magnesium oxide
Study: 26674497
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (oxycodone and pregabalin) plus placebo
Study: 22930240
Drug: PTH(1-84) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) treatment over 24 months
Study: 22930240
Drug: PTH(1-84) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) treatment with ≥80% adherence
Study: 22930240
Drug: PTH(1-84) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) treatment
Study: 22930240
Drug: Post-discontinuation of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation of PTH(1-84) treatment
Study: 20854662
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg s.c. biweekly)
Study: 19016147
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (group 2)
Study: 10781640
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (n=15)
Study: 10781640
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg simvastatin (n=15)
Study: 10781640
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n=15)
Study: 8782136
Drug: Intraarticular local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular local anesthetic (bupivacaine 0.25%, 5 ml)
Study: 2937131
Drug: Intramuscular medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular medroxyprogesterone acetate (MPA) 500 mg/day for at least two months after the operation
Study: 2937131
Drug: MPA 500
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 500 mg/3 times a week for one year
Study: 29846031
Drug: Pharmacy-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacy-based intervention including medication review, regular dose dispensing, and counselling regarding medication use and symptoms of heart failure.
Study: 26916877
Drug: Daily Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily Teriparatide (TPTD)
Study: 18687376
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor (DRD2) 957C>T polymorphism
Study: 7759412
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of ketoprofen
Study: 232024
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitors SQ 20881 and captopril
Study: 26248655
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (InGaAlP laser, 650 nm, 100 mW, 2 J per point, applied from the first day of conditioning until D + 5)
Study: 26248655
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (simulated laser treatment)
Study: 21586498
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 30 min each morning for 11 days
Study: 15901744
Drug: Eniporide (2.5-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniporide (2.5-400 mg)
Study: 15772362
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (IT)
Study: 6351027
Drug: Erythrityl tetranitrate
Normalized name: Erythrityl tetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrityl tetranitrate (ETN) 5 mg
Study: 30616791
Drug: Primary radiotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiotherapy with concurrent chemotherapy (CRT)
Study: 30616791
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with definitive RT
Study: 28471697
Drug: Pirfenidone 2,403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone 2,403 mg/d
Study: 20137430
Drug: Levofloxacin sensitivity
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin sensitivity (G(+)C)
Study: 20137430
Drug: Levofloxacin sensitivity
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin sensitivity (G(-)B)
Study: 17725542
Drug: ALA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA group (20 mg/kg body weight of 5-aminolevulinic acid)
Study: 10975044
Drug: Multi-injection protocol
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-injection protocol for correcting postprandial blood glucose
Study: 8869411
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (50 ml/kg for 1 h) in acute study
Study: 1948810
Drug: RU 28318
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 28318 (160 mg)
Study: 1948810
Drug: Spironolactone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (80 mg)
Study: 29403268
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine
Study: 29403268
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline
Study: 29403268
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 2% lidocaine and 2 mL normal saline
Study: 21833684
Drug: Glenohumeral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenohumeral steroid injections (Group B)
Study: 20587725
Drug: Hypoglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (blood glucose 2.5 mmol/l) in nondiabetic participants
Study: 20587725
Drug: Hypoglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (blood glucose 2.5 mmol/l) in type 1 diabetes
Study: 16122457
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin (both)
Study: 16122457
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only (n = 598)
Study: 16122457
Drug: Neither medication
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither medication (n = 236)
Study: 8890804
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of dipyridamole
Study: 1985721
Drug: VAP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAP chemotherapy (vincristine, doxorubicin, and prednisone) with radiotherapy for local relapse
Study: 1985721
Drug: Triple-drug intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug intrathecal therapy and regimens of 6-thioguanine and cytarabine alternating with vincristine, prednisone, cyclophosphamide, and cytarabine
Study: 1985721
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for testicular relapse
Study: 6368649
Drug: Continuous ASA
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ASA treatment
Study: 6368649
Drug: Desensitization to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitization to ASA followed by ASA treatment
Study: 29952408
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous propofol anaesthesia (TIVA), n = 31
Study: 26473667
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) 30 mg BID + Asunaprevir (ASV) 200 mg BID + Beclabuvir (BCV) 150 mg BID
Study: 20374607
Drug: 6-monthly cytological
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly cytological screening in primary care
Study: 16926382
Drug: Maximal ADP
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal ADP stimulated respiration with FA-derived substrate (palmitoyl-l-carnitine + malate)
Study: 14964744
Drug: efalizumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: efalizumab 1.0 mg/kg/wk
Study: 3898805
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g brewer's yeast
Study: 22290273
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg daily for 21 days followed by single-dose ridaforolimus 40 mg on day 14
Study: 22290273
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg daily for 14 days followed by single-dose ridaforolimus 2 mg on day 2
Study: 16022174
Drug: Coumadin Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin Aspirin Reinfarction Study
Study: 10434166
Drug: Theophylline administration
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline administration (6 mg kg‐1 infused over 7.5 min)
Study: 7607766
Drug: celiprolol 200‐400
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol 200‐400 mg/day
Study: 7607766
Drug: metoprolol 100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100‐200 mg/day
Study: 2094056
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone substitution and Cavinton adjuvant therapy
Study: 2094056
Drug: Hormone substitution
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone substitution therapy
Study: 27077693
Drug: STAND (Supporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAND (Supporting Teens' Autonomy Daily)
Study: 15766366
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) b.i.d. for 3 months
Study: 14670773
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone (rGH) treatment, 1 IU/kg/week, administered via daily subcutaneous injections for 12 months.
Study: 8880055
Drug: Citalopram (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10, 20, 40, 80 mg)
Study: 8880055
Drug: Fluoxetine (3-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (3-week intervals)
Study: 8880055
Drug: Fluvoxamine (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (25, 50, 100, 200 mg)
Study: 8880055
Drug: Paroxetine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10, 20, 40, 80 mg)
Study: 6347173
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (antacid and placebo)
Study: 30459575
Drug: Intramuscular Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Electrical Stimulation (EIMS) at 2 Hz for ten sessions
Study: 30459575
Drug: Intramuscular Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Electrical Stimulation (EIMS)
Study: 16238217
Drug: Conventional cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Study: 16238217
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Study: 12404887
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dequalinium chloride, treated once per day for 6 days
Study: 12404887
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg povidone iodine, treated once per day for 6 days
Study: 9593495
Drug: Selective dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective dorsal rhizotomy (SDR) and therapy (PT and OT)
Study: 9593495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) receiving physiotherapy (PT) and occupational therapy (OT)
Study: 2963509
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone premedication
Study: 30721201
Drug: Traditional neuroprotective
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional neuroprotective therapy
Study: 24622716
Drug: SYR-472 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 12.5 mg
Study: 24622716
Drug: SYR-472 25
Normalized name: petrolatum 0.472 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 25 mg
Study: 24622716
Drug: SYR-472 50
Normalized name: petrolatum 0.472 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 50 mg
Study: 24622716
Drug: SYR-472 100
Normalized name: petrolatum 0.472 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 100 mg
Study: 24622716
Drug: SYR-472 200
Normalized name: petrolatum 0.472 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 200 mg
Study: 23011525
Drug: Monotherapy (valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (valsartan or amlodipine)
Study: 23011525
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (including hydrochlorothiazide)
Study: 23011525
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy controlled vs uncontrolled
Study: 17350216
Drug: Lipo-ecraprost (60-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo-ecraprost (60-microg dose administered intravenously starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)